Reynoso Jamie L. sold $9K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 2,006 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.63 on 2026-10-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Oct 7, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

A small insider sale by the CEO may cause minor short-term price pressure but is unlikely to affect long-term valuation.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

CEO may be diversifying holdings; the transaction size is negligible relative to total shares owned.

Relevance 2/10Novelty 2/10Timing: same day

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

CEO Reynoso Jamie L. sold 2,006 shares for $9,287 in a routine Form 4 insider sale.

Expected impact

likely slight pressure as market may view the sale negatively

Evidence & confidence

The sale size is small ($9k) and unlikely to move the stock significantly, but any insider sell can cause modest downside sentiment.

Market effects

No material impact on the healthcare sector.

No regional effect.

No global relevance.

Counterpoint

The sale could be a routine portfolio rebalancing and not a negative signal.

Key entities

  • Reynoso Jamie L.

    CEO of Clover Health Investments

  • Clover Health Investments, Corp.

    US-listed health technology company (ticker CLOV)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.